Gold prices fall as geopolitical tensions ease; U.S. CPI looms
Incyte (NASDAQ:INCY) Executive Vice President and General Manager US, Barry P. Flannelly, sold 1,192 shares of company stock on July 15, 2025, at a price of $69.86, totaling approximately $83,273. The transaction comes as the $13.4 billion biotech company maintains strong financial health, with InvestingPro data showing robust liquidity and minimal debt levels.
According to a Form 4 filing with the Securities and Exchange Commission, Flannelly also disposed of 922 and 1,141 shares on July 14 and July 15, respectively, to cover tax withholding obligations. These shares were sold at prices ranging from $68.25 to $69.98, amounting to $142,394. The stock currently trades near its 52-week high of $83.95, with the company’s next earnings report scheduled for July 29, 2025. For deeper insights into Incyte’s valuation and financial metrics, check out the comprehensive research available on InvestingPro.
Following these transactions, Flannelly directly owns 36,489 shares of Incyte. This includes an aggregate of 35,136 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
In other recent news, Incyte has announced significant leadership changes with the appointment of Bill Meury as the new President and Chief Executive Officer, succeeding Hervé Hoppenot. Meury, who has a robust background in the biopharmaceutical industry, takes over as Hoppenot retires after 11 years, during which Incyte expanded its revenue from $355 million in 2013 to $4.2 billion. UBS has raised its price target for Incyte to $62 from $61, reflecting slightly higher sales projections for the Niktimvo product, although the firm maintained a Neutral rating. The leadership transition has been positively received by investors, as noted by William Blair, which reiterated its Market Perform rating on the stock. Citi also maintained its buy rating and $88 price target, expressing a positive outlook on the company’s future under Meury’s leadership. These developments come as Incyte continues to navigate challenges such as the loss of exclusivity for its Jakafi product. Lead Independent (LON:IOG) Director Julian Baker has been elected Chairman of the Board, further solidifying the company’s strategic leadership team. Analysts from William Blair have indicated that Meury’s approach to Incyte’s pipeline will be closely watched, particularly regarding its potential to drive growth beyond Jakafi.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.